Geneious
Auckland, New Zealand· Est.
A comprehensive, AI‑enhanced bioinformatics suite that streamlines sequence analysis and antibody discovery for life‑science researchers.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A comprehensive, AI‑enhanced bioinformatics suite that streamlines sequence analysis and antibody discovery for life‑science researchers.
Antibody engineeringGenomicsMolecular biology
Technology Platform
An integrated, plugin‑based bioinformatics suite with AI‑enhanced antibody discovery workflows that combine sequence analysis, cloning design, and data management in a single, cloud‑collaborative environment.
Opportunities
Expanding AI‑driven antibody discovery and cloud collaboration tools positions Geneious to capture additional market share in biologics R&D and academic genomics.
Risk Factors
Intense competition from larger, well‑funded bioinformatics platforms and the need for continuous innovation to keep pace with rapidly evolving AI and sequencing technologies.
Competitive Landscape
Geneious competes with Benchling, CLC Genomics Workbench, and DNASTAR, differentiating through its user‑friendly UI, extensive plugin ecosystem, and recent AI‑focused antibody discovery capabilities.